US FDA Oncology Center Wants Trial Datasets Flagged As Remote Or In-Person Assessments

Agency wants to use pandemic-interrupted clinical trials to gauge how decentralized approaches impacted study integrity and to inform prospective use of such designs post-COVID.

Flags red and green
Special flags for 'remote' and 'trial site' assessments in cancer trial datasets will inform the use of decentralized approaches going forward. • Source: Shutterstock

The US Food and Drug Administration's oncology center intends to leverage datasets from cancer studies interrupted by the COVID-19 pandemic to advance the use of decentralized clinical trial approaches.

The Oncology Center of Excellence is requesting that applicants submitting data in support of new drug applications or biologic license applications voluntarily add flags to distinguish between

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D

Unlocking Opportunities: How To Engage With The EMA On Animal Testing Alternatives

 

The European Medicines Agency, like its counterpart in the US, is increasingly focusing on the use of alternatives to animal testing.

EU Pharma Reform: Exclusivity Vouchers Alone Are Insufficient Incentive For Antimicrobials, Industry Says

 

European pharma trade associations EFPIA and EUCOPE outline their respective views on how the EU’s pharma legislation overhaul should tackle antimicrobial resistance, and why transferable exclusivity vouchers alone will not suffice as incentives.

What The EMA Can Teach HTA Bodies About Joint Clinical Assessments

 

EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.